SHR-A1811 plus AK112

Phase 2Small molecule

SSun Yat-sen University

SHR-A1811 plus AK112 is one of 8 small molecule programs targeting Metastatic NSCLC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic NSCLCNot yet recruiting

Metastatic NSCLCPhase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Metastatic NSCLC

#DrugCompanyPhaseTrials

Libtayo

Regeneron

Phase 3

1 2

Opdivo

Bristol-Myers Squibb

Phase 2

5 3

Yervoy

Bristol-Myers Squibb

Phase 2

3 4

Tecentriq

Roche

Phase 2

1 5

Cyramza

Eli Lilly

Phase 2

1 6

Repatha

Amgen

Phase 2

1 7

Cabometyx

Bristol-Myers Squibb

Phase 2

1 8

SHR-A1811 plus AK112

SSun Yat-sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Metastatic NSCLC

NCT07489703

Clinical

Trials by Indication[1]

Metastatic NSCLC1 trial

SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07489703·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHR-A1811 plus AK112. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-A1811 plus AK112 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-A1811 plus AK112. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

SHR-A1811 plus AK112

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News